期刊
NUCLEIC ACIDS RESEARCH
卷 41, 期 1, 页码 125-138出版社
OXFORD UNIV PRESS
DOI: 10.1093/nar/gks971
关键词
-
资金
- CHRU de Lille
- Region Nord/Pas-de-Calais
- Institut National du Cancer (INCa)
- Fonds Europeen de Developpement Regional (FEDER, European Community)
- Ligue Nationale Contre le Cancer (Comite du Pas-de-Calais, Septentrion)
- Association Laurette Fugain
- Association pour la Recherche sur le Cancer
- NIH NIAID [064200]
- IRCL
Direct modulation of gene expression by targeting oncogenic transcription factors is a new area of research for cancer treatment. ERG, an ETS-family transcription factor, is commonly over-expressed or translocated in leukaemia and prostate carcinoma. In this work, we selected the di-(thiophene-phenyl-amidine) compound DB1255 as an ERG/DNA binding inhibitor using a screening test of synthetic inhibitors of the ERG/DNA interaction followed by electrophoretic mobility shift assays (EMSA) validation. Spectrometry, footprint and biosensor-surface plasmon resonance analyses of the DB1255/DNA interaction evidenced sequence selectivity and groove binding as dimer. Additional EMSA evidenced the precise DNA-binding sequence required for optimal DB1255/DNA binding and thus for an efficient ERG/DNA complex inhibition. We further highlighted the structure activity relationships from comparison with derivatives. In cellulo luciferase assay confirmed this modulation both with the constructed optimal sequences and the Osteopontin promoter known to be regulated by ERG and which ERG-binding site was protected from DNaseI digestion on binding of DB1255. These data showed for the first time the ERG/DNA complex modulation, both in vitro and in cells, by a heterocyclic diamidine that specifically targets a portion of the ERG DNA recognition site.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据